(Agoura
Hills, CA) Just recently in
history, A2 Biotherapeutics, Inc. emerged out of stealth mode. Fascinatingly, it was in stealth mode since
the year 2018; when this business was founded.
The founders were ex-employees of Amgen, Inc. The previous, is an American multinational
biopharmaceutical business. It is
commonly known as the proprietor of immunostimulator medication, which is used
to prevent infections in patients, who are undergoing cancer chemotherapy
treatment. Therefore and as a result,
early in the stealth mode stage, A2 Biotherapeutics, Inc. became infused with a
deep passion for cancer research. Since
the emergence out of stealth mode, A2 Biotherapeutics, Inc. has become the
proud proprietor, of a technology platform.
The A2 Biotherapeutics’ technology platform aims at the development of a
pipeline, of selective tumor cell therapeutics.
Recently, A2 Biotherapeutics, Inc. announced that, it desires to develop
innovative cell therapies for cancer patients.
Specifically, the aforementioned business revealed that, it has secured
$57 million USD in a Series A funding round.
The most noteworthy new investors of the aforementioned business are The
Column Group, Vida Ventures, Samsara Bio Capital and Nextech Invest.
Nextech Invest, Samsara Bio Capital,
Vida Ventures and The Column Group as the most noteworthy new investors; will
be contributing funds. The funds will be
used for the following one thing. The
one thing is the continuation of the business launch. In reference to, the continuation of the
business launch, the aforementioned involves advancing the product
candidates. In order to accomplish this
task, the funds will pay for a fully integrated discovery, development and
manufacturing facility. The facility, in
turn, will house the organization of the business. Additionally and currently, the organization
employs more than 40 staff members. In
other words, A2 Biotherapeutics, Inc. is going to finish building up and
launching.
However and returning to, A2
Biotherapeutics’ technology platform, the aforementioned is made possible by
licensed technology. The licensed
technology is from Innovative Targeting Solutions. This business has its headquarters office in
Vancouver, the Country of Canada.
Specifically, and what the technology platform does, is identify rare
binders. These rare binders are derived
from antibodies, T.C.R.s, precision binder engineering, precision binder
optimization and binder modular design.
Helping the technology platform, are A2 Biotherapeutics’ proprietary
binders. A2 Biotherapeutics’ binders are
antibody fragments, and, T.C.R. fragments that; bind to the targeted cancer
cells. Overall, A2 Biotherapeutics’
technology platform is highlighted by the following four things. The first thing; it determines the content of
T cell proliferation, cytotoxicity and survival. For survival, it means acutely or over
time. The second thing, it is able to
enrich the binders. The goal is to optimize
the binders’ most important parameters, in regards to cell therapy. The third thing, it is able to process modular
constructs. The goal is to integrate
multiple signals, in order, to provide a large therapeutic window. The fourth thing, it has two major types of
signal integration. The first type is a
molecular integrator that, has a single bispecific molecule. The second type is a cellular integrator that,
has two independent modules.
To end, A2 Biotherapeutics, Inc. did
release press statements. Madhu
Balachandran is a Member of A2 Biotherapeutics’ Board of Directors. Through a press statement, Ms./Mrs. Balachandran
said the following. “A2 Biotherapeutics
aspires to increase speed to patients and reduce cost of goods by leveraging
its cell therapy manufacturing expertise and advances in technology.” Scott Foraker is the President and the Chief
Executive Officer of A2 Biotherapeutics, Inc.
Through a press statement, Mr. Foraker said the following. “Our unique approach to targeted killing of
tumor cells has the potential to create breakthrough cancer therapies that we
look forward to bringing to patients, particularly those in need of new
approaches.” Alexander Kamb is a
Co-Founder and the Chief Scientific Officer of A2 Biotherapeutics, Inc. Through a press statement, Mr. Kamb said the
following. “This approach has the
promise of being utilized for multiple tumor types, providing solutions for
many cancer patients. A2 Biotherapeutics
has potent, highly selective binders that we combine into molecular constructs
to integrate multiple signals and potentially provide a large therapeutic
window.” As previously stated, A2
Biotherapeutics, Inc. recently announced that, it desires to develop innovative
cell therapies for cancer patients.
Specifically, the aforementioned business revealed that, it has secured
$57 million USD in a Series A funding round.
Lastly; the most noteworthy new investors of the aforementioned business
are The Column Group, Vida Ventures, Samsara Bio Capital and Nextech
Invest.
###
Written
from Press Release
Registered
Writer with
PR
Newswire Association, LLC
R-Berumen28
11/09/2019
To Purchase
Newspaper/Magazine Articles from this Author,
Please
Use this Link:
To
Read Exclusive and Only-Subscriber Articles,
Please
Use this Link to Coil.com:
Post a Comment